Ruxolitinib
Uses of Ruxolitinib
Ruxolitinib is commonly used to treat Chronic Idiopathic Myelofibrosis and Polycythemia Vera.
How Ruxolitinib Works
Ruxolitinib is a selective Janus Associated Kinase (JAK) inhibitor which helps to mediate immune function and haematopoiesis. This is particularly helpful in patients with myelofibrosis and polycythemia vera which are characterized by abnormal JAK activity.
Side Effects of Ruxolitinib
Decreased in red blood cells/white blood cells/platelets, Increased risk of infections, Increased cholesterol and triglycerides level, Difficulty in breathing, Gut disturbances, Liver enzyme dysfunction, Weight gain, Oedema, Muscle spasm, Headache, Dizziness, Insomnia
Warnings
Kidney Use With Care
Dose adjustment is needed for patients with severe and end-stage kidney disease on dialysis. Please consult your doctor.
Alcohol Not Advisable
There is no known interaction between alcohol and Ruxolitinib when consumed concomitantly. However, it is not advisable to consume alcohol when receiving anticancer treatment.
Pregnancy Not Safe
Animal studies have shown reproductive toxicities but there are no human studies have been conducted. Thus, Ruxolitinib is contraindicated during pregnancy. Please consult your doctor.
Driving Generally Safe
Ruxolitinib usually does not affect the ability to drive. Do not drive unless you are feeling well.
Liver Use With Care
Dose adjustment is needed in patients with liver impairment. Please consult your doctor.
Lactation Not Advisable
Excretion of Ruxolitinib has been found in animal milk but it is unknown in human breast milk. Thus, it is not advisable to be used during breastfeeding as the risks cannot be excluded. Please consult your doctor.
Written by Dr Sri Viknarajan, MD (Universiti Hasanuddin, Indonesia)
Reviewed by Dr Nur Syuhada binti Zulkifli, MD, Universiti Kebangsaan Malaysia (UKM).
